Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research

Summary

The patients with non-resectable colorectal liver metastases (CRLM) have always being considered a particular subgroup of CRLM in which the therapeutic approach, is focused on strategies that allow a potential surgery like neoadjuvant systemic treatments. But, the underlying biology that causes this particular profile of spread in a proportion of patients that always recur and progress in the liver has not been properly characterized from a biological point of view. Unfortunately, these patients finally develop liver metastasis not amenable for local treatments and become refractory to systemic treatments even without developing extrahepatic liver metastases. As a result, liver transplantation (LT) is a potential for patients without extrahepatic involvement and nonresectable CRLM. There are several studies that aims to evaluate if LT increases overall survival compared to best alternative care. To our knowledge, none of these studies incorporate objectives focused on the underlying tumor biology of this particular population and the development of focused strategies including a dynamic disease monitoring and targeted treatments for this particular population.The METLIVER trial will permit to expand the genetic studies to the whole complexity of metastatic lesions and a more precise evaluation of their genetic heterogeneity. Moreover, it will help to precise the type of genetic analyses on liquid biopsies that can be designed for patients that will unfortunately relapse mostly with lung metastases after LT. Our proposal will maximize the opportunity to produce an unprecedented knowledge on CRLM evolution and will provide new opportunities for relapsed patients.

Conditions

• Colorectal Cancer
• Liver Metastases
• Genetic Change

Interventions

OTHER

Liver transplantation

Liver transplantation

Sponsors & Collaborators

• Hospital Vall d'Hebron

  lead OTHER

Principal Investigators

• Ramón Charco · Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron

• Elena Elez · Department of Oncology, Hospital Universitario Vall d´Hebron

• Cristina Dopazo · Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron

• Ernest Hidalgo · Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron

• Itxarone Bilbao · Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron

• Concepción Gómez-Gavara · Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron

• Mireia Caralt · Department of HPB Surgery and Transplants, Hospital Universitario Vall d´Hebron

• Javier Ros · Department of Oncology, Hospital Universitario Vall d´Hebron

• Francesc Salva · Department of Oncology, Hospital Universitario Vall d´Hebron

• Isabel Campos-Varela · Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d´Hebron

• Lluis Castells · Liver Unit, Department of Internal Medicine, Hospital Universitario Vall d´Hebron

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-01-01

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• Spain

Study Locations